BioCentury | Feb 8, 2016
Clinical News

EscharEx: Phase II data

...data from a single-blind, Israeli and European Phase II trial in 73 patients showed that EscharEx...
...vehicle (55% vs. 29%, p=0.047). Additionally, 50% of patients with diabetic foot ulcers treated with EscharEx...
...venous leg ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Product: EscharEx...
BioCentury | Sep 7, 2015
Clinical News

EscharEx: Completed Phase II enrollment

...enrollment of 73 patients in the double-blind, vehicle-controlled, Israeli and European Phase II trial evaluating EscharEx...
...ulcers, venous ulcers and postsurgical or traumatic hard-to-heal wounds. MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Product: EscharEx...
BioCentury | Jun 2, 2014
Clinical News

EscharEx: Phase II started

...MediWound began a double-blind, vehicle-controlled, Israeli Phase II trial to evaluate EscharEx in about 72 patients...
...ulcers, venous ulcers and post-surgical or traumatic hard-to-heal wounds. MediWound Ltd. (NASDAQ:MDWD), Yavne, Israel Product: EscharEx...
Items per page:
1 - 3 of 3